A Systematic Review of the Efficacy of Centella asiatica for Improvement of the Signs and Symptoms of Chronic Venous Insufficiency

Table 1

Characteristics of RCT on CVI and microangiopathy included in this study.

Study	Participants	Intervention (dose)	𝑛	Duration of study	Control
Allegra et al., 1981 [38]	Patients with venous insufficiency of the lower limbs	TTFCA (60 mg/day)	80	30 days	placebo
Marastoni et al., 1982 [39]	Patients with CVI	Centella asiatica extract (tid)*	17	4 weeks	tribenoside
Pointel et al., 1987 [40]	Patients with venous insufficiency of the lower limbs	TTFCA (60 mg; 120 mg)	94	8 weeks	placebo
Cesarone et al., 1994 [41]	Patients with chronic venous hypertensive microangiopathy	TTFCA (30 mg bid; 60 mg bid)	90	60 days	placebo
Cesarone et al., 2001 [42]	Patients with severe venous hypertension, ankle swelling, and lipodermatosclerosis	TTFCA (60 mg bid)	40	8 weeks	placebo
Cesarone et al., 2001 [43]	Patients with venous hypertension with ankle and foot swelling, oedema, and lipodermatosclerosis, with intact skin	TTFCA (60 mg bid)	40	6 weeks	placebo
De Sanctis et al., 2001 [44]	Patients with venous hypertension (ambulatory venous pressure > 42 mm Hg)	TTFCA (30 mg tid; 60 mg tid)	62	4 weeks	placebo
Incandela et al., 2001 [45]	Patients with venous hypertensive microangiopathy	TTFCA (60 mg daily; 120 mg daily)	99	8 weeks	placebo

TTFCA: total triterpenic fraction of Centella asiatica.
*Extract dosage not reported.